NasdaqCM:AEMD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Aethlon Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AEMD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: AEMD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-11.1%

AEMD

-2.7%

US Medical Equipment

-3.2%

US Market


1 Year Return

-22.7%

AEMD

31.8%

US Medical Equipment

38.9%

US Market

Return vs Industry: AEMD underperformed the US Medical Equipment industry which returned 29.5% over the past year.

Return vs Market: AEMD underperformed the US Market which returned 37.1% over the past year.


Shareholder returns

AEMDIndustryMarket
7 Day-11.1%-2.7%-3.2%
30 Day-12.5%-0.5%-0.8%
90 Day27.5%7.3%3.1%
1 Year-22.7%-22.7%32.9%31.8%42.0%38.9%
3 Year-89.6%-89.6%76.8%72.3%60.6%50.3%
5 Year-97.2%-97.2%151.1%132.6%128.0%102.5%

Long-Term Price Volatility Vs. Market

How volatile is Aethlon Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aethlon Medical undervalued compared to its fair value and its price relative to the market?

2.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AEMD is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AEMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AEMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AEMD is good value based on its PB Ratio (2.4x) compared to the US Medical Equipment industry average (5.3x).


Next Steps

Future Growth

How is Aethlon Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-47.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AEMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AEMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AEMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AEMD's revenue is expected to decline over the next 3 years (-8.2% per year).

High Growth Revenue: AEMD's revenue is forecast to decline over the next 3 years (-8.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AEMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aethlon Medical performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AEMD is currently unprofitable.

Growing Profit Margin: AEMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AEMD is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare AEMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AEMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.8%).


Return on Equity

High ROE: AEMD has a negative Return on Equity (-64.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aethlon Medical's financial position?


Financial Position Analysis

Short Term Liabilities: AEMD's short term assets ($12.3M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: AEMD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AEMD is debt free.

Reducing Debt: AEMD has no debt compared to 5 years ago when its debt to equity ratio was 16.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AEMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AEMD has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 2.6% each year.


Next Steps

Dividend

What is Aethlon Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AEMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AEMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AEMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AEMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AEMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Chuck Fisher (73 yo)

0.33

Tenure

US$159,000

Compensation

Dr. Charles J. Fisher, Jr., also known as Chuck, M.D. has been Chief Executive Officer of Aethlon Medical, Inc. since October 30, 2020. He founded and serves as the Chief Executive Officer of Margaux Biolo...


Leadership Team

NamePositionTenureCompensationOwnership
Charles Fisher
CEO, Director & Member of Extracorporeal Therapy Advisory Board0.33yrUS$159.00k0.13%
$ 36.4k
James Frakes
CFO, Senior VP of Finance & Secretary10.42yrsUS$354.75k0.020%
$ 5.5k
Guy Cipriani
Senior VP2.67yrsUS$69.00k0.12%
$ 32.6k
Sunil Sawhney
Head of Clinical Studies15.92yrsno datano data
Steven Larosa
Chief Medical Officer0.083yrno datano data
Richard Tullis
Consultantno datano datano data

0.3yrs

Average Tenure

68yo

Average Age

Experienced Management: AEMD's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Charles Fisher
CEO, Director & Member of Extracorporeal Therapy Advisory Board0.33yrUS$159.00k0.13%
$ 36.4k
Guy Cipriani
Senior VP2.67yrsUS$69.00k0.12%
$ 32.6k
Edward Broenniman
Chairman of the Board0.33yrUS$79.00k0.14%
$ 39.3k
Nathan Levin
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Gregory T. Kovacs
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Claudio Ronco
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Larry Cowgill
Member of Sepsis & Inflammation Advisory Boardno datano datano data
John Kellum
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Chetan Shah
Independent Director7.67yrsUS$78.00k0.063%
$ 17.7k
David Ward
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Irshad Chaudry
Member of Sepsis & Inflammation Advisory Boardno datano datano data
Geert Schmid-Schönbein
Member of Sepsis & Inflammation Advisory Boardno datano datano data

3.0yrs

Average Tenure

62yo

Average Age

Experienced Board: AEMD's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AEMD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31%.


Top Shareholders

Company Information

Aethlon Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aethlon Medical, Inc.
  • Ticker: AEMD
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$28.127m
  • Shares outstanding: 12.12m
  • Website: https://www.aethlonmedical.com

Number of Employees


Location

  • Aethlon Medical, Inc.
  • 9635 Granite Ridge Drive
  • Suite 100
  • San Diego
  • California
  • 92123
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AEMDNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1999
EJUBST (Boerse-Stuttgart)YesCommon StockDEEURMar 1999
EJUDB (Deutsche Boerse AG)YesCommon StockDEEURMar 1999

Biography

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopur...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/26 00:01
End of Day Share Price2021/02/25 00:00
Earnings2020/12/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.